

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

BIOPHAN TECHNOLOGIES INC
Form 10-Q/A
January 24, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q
Amendment #1

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934

For the quarterly period ended: November 30, 2005

OR

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File No. 0-26057

BIOPHAN TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Nevada

82-0507874

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer Identification No.)

150 Lucius Gordon Drive, Suite 215
West Henrietta, New York
14586

(Address of principal executive offices)
(Zip Code)

(585) 214-2441

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

Indicate the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date.

Class outstanding as of January 12, 2006- Common Stock, \$.005 par value:
81,805,243 shares

EXPLANATORY NOTE

We are filing this Amendment #1 to our Quarterly Report on Form 10-Q for the quarterly period ended November 30, 2005 for the following purposes:

- (a) In Part I, Item 1, Financial Statements, to restate our financial statements to reflect a change in our accounting for our investment in Myotech, LLC a development stage company, and a developer of cardiac assist technologies. FASB Interpretation No. 46 (FIN-46R) (Revised December 2003), Consolidation of Variable Interest Entities, requires that if an enterprise is the primary beneficiary of a variable interest entity, the assets, liabilities and results of operations of the variable interest entity should be included in the consolidated financial statements of the enterprise. On November 30, 2005 we acquired 3,768,488 Class A (voting) units of Myotech (representing a 35% equity interest), in exchange for 4,923,080 shares of our common stock valued at \$8,467,698. This investment was previously accounted for using the equity method.

We have determined that Myotech is a variable interest entity in accordance with FIN-46R and have concluded that we are the primary beneficiary as defined by FIN-46R. As a result, we are required to consolidate Myotech as of the date of acquisition of November 30, 2005. Therefore, the consolidated financial statements included in this amended Quarterly Report on Form 10-Q have been restated to include the accounts of Myotech.

- (b) In Part I, Item 4, Controls and Procedures, to disclose our conclusions regarding the effectiveness of our financial reporting controls and procedures.
- (c) In Part I, Item 2, Management's Discussion and Analysis of Financial Condition and Results of Operations, to amend the financial analyses to reflect the restatement of financial statements as explained above.
- (d) To amend such other financial information included elsewhere as affected by the restatement of our financial statements.

INDEX

| | Page Number |
|---|----------------|
| PART I FINANCIAL INFORMATION | |
| ITEM 1. Financial Statements | |
| Report of Independent Registered Public Accounting Firm | 1 |

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

| | |
|--|----|
| Condensed Consolidated Balance Sheets, November 30, 2005 (Unaudited) and February 28, 2005 | 2 |
| Condensed Consolidated Statements of Operations, Three Months and Nine Months Ended November 30, 2005 and 2004 (Unaudited), and from August 1, 1968 (Date of Inception) through November 30, 2005 (Unaudited) | 3 |
| Condensed Consolidated Statements of Cash Flows, Nine Months Ended November 30, 2005 and 2004 (Unaudited) and from August 1, 1968 (Date of Inception) through November 30, 2005 (Unaudited) | 4 |
| Notes to Condensed Consolidated Financial Statements | 6 |
| ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations | 8 |
| ITEM 3. Quantitative and Qualitative Disclosures About Market Risk | 12 |
| ITEM 4. Controls and Procedures | 12 |
| PART II. OTHER INFORMATION | 13 |
| ITEM 1. Legal Proceedings | 13 |
| ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds | 13 |
| ITEM 3. Defaults Upon Senior Securities | 13 |
| ITEM 4. Submission of Matters to a Vote of Security Holders | 13 |
| ITEM 5. Other Information | 13 |
| ITEM 6. Exhibits | 13 |
| SIGNATURES | 15 |

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors
Biophan Technologies, Inc.

We have reviewed the accompanying condensed consolidated balance sheet of Biophan Technologies, Inc. and Subsidiaries (the "Company") as of November 30, 2005, and the related condensed consolidated statements of operations for the three-month and nine-month periods ended November 30, 2005 and 2004 and the condensed consolidated statements of cash flows for the nine month periods ended November 30, 2005 and 2004. These interim financial statements are the responsibility of the Company's management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with standards of the Public Company Accounting Oversight Board, the objective of which is the expression of an opinion regarding the consolidated financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the accompanying condensed consolidated interim financial statements for them to be in conformity with accounting principles generally accepted in the United States of America.

We have previously audited, in accordance with standards of the Public Company Accounting Oversight Board, the consolidated balance sheet of Biophan Technologies, Inc. and Subsidiaries as of February 28, 2005, and the related consolidated statements of operations, stockholders' equity, and cash flows for the year then ended and the amounts included in the cumulative column in the consolidated statements of operations and cash flows for the period from March 1, 2000 to February 28, 2005 (not presented herein). In our report dated April 6, 2005, except for Note 13 to the financial statements as to which the date was May 27, 2005, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of February 28, 2005, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

As described in the Note to the Condensed Consolidated Financial Statements, under the caption "Investment in Myotech, LLC and Restatement of Financial Statements", the Company has restated its financial statements as of November 30, 2005.

GOLDSTEIN GOLUB KESSLER LLP
New York, New York

December 28, 2005, except for the caption "Investment in Myotech, LLC and Restatement of Financial Statements", as to which the date is January 23, 2007

1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY) CONDENSED CONSOLIDATED BALANCE SHEETS

| | November 30, 2005 | February 28, 2005 |
|-------------------------------|---------------------------|-------------------|
| ASSETS | (Unaudited) (Restated) | |
| | ----- | ----- |
| Current assets: | | |
| Cash and cash equivalents | \$ 2,606,784 | \$ 753,288 |
| Stock subscription receivable | -- | 900,000 |
| Due from related parties | 27,536 | 220,959 |
| Prepaid expenses | 175,941 | 91,596 |
| Other current assets | 84,670 | 41,338 |
| | ----- | ----- |
| Total current assets | 2,894,931 | 2,007,181 |

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

| | | |
|--|---------------|--------------|
| Property and equipment, net | 125,430 | 73,518 |
| Other assets: | | |
| Intangible assets, net of amortization: | | |
| Myotech, LLC | 24,795,968 | -- |
| Other | 1,423,392 | 997,738 |
| Investment in New Scale Technologies, Inc. | 100,000 | 100,000 |
| Security deposit | 6,049 | 2,933 |
| Deferred tax asset, net of valuation allowance of \$6,804,000 and \$4,787,000, respectively | -- | -- |
| | ----- | ----- |
| | 26,325,409 | 1,100,671 |
| | ----- | ----- |
| | \$ 29,345,770 | \$ 3,181,370 |
| | ===== | ===== |

LIABILITIES AND STOCKHOLDERS' EQUITY

| | | |
|---|---------------|--------------|
| Current liabilities: | | |
| Accounts payable and accrued expenses | \$ 1,928,211 | \$ 1,037,103 |
| Note payable | 15,886 | 200,000 |
| Line of credit - related party | 500,000 | -- |
| Deferred revenues | 500,000 | 225,000 |
| | ----- | ----- |
| Total current liabilities | 2,944,097 | 1,462,103 |
| Minority interest | 15,752,248 | -- |
| Stockholders' equity: | | |
| Common stock \$.005 par value | | |
| Authorized, 125,000,000 shares | | |
| Issued, 81,683,243 and 74,317,832 shares, respectively | 408,416 | 371,589 |
| Stock subscription receivable | -- | (150,000) |
| Additional paid-in capital | 48,001,998 | 18,982,952 |
| | ----- | ----- |
| | 48,410,414 | 19,204,541 |
| Less treasury stock, 4,923,080 shares | (8,467,698) | -- |
| | ----- | ----- |
| | 39,942,716 | 19,204,541 |
| Deficit accumulated during the development stage | (29,293,291) | (17,485,274) |
| | ----- | ----- |
| | 10,649,425 | 1,719,267 |
| | ----- | ----- |
| | \$ 29,345,770 | \$ 3,181,370 |
| | ===== | ===== |

See Notes to Condensed Consolidated Financial Statements.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

| | Three Months Ended November 30, | | Nine Months Ended November 30, | |
|---|------------------------------------|-----------------------|-----------------------------------|-----------------------|
| | 2005 | 2004 | 2005 | 2004 |
| Revenues: | | | | |
| Development payments | \$ 225,000 | \$ -- | \$ 225,000 | \$ -- |
| License fees | 187,500 | -- | 250,000 | -- |
| Operating revenue of European subsidiary | 54,435 | -- | 113,119 | -- |
| | <u>466,935</u> | <u>--</u> | <u>588,119</u> | <u>--</u> |
| Operating expenses: | | | | |
| Research and development | 1,212,239 | 685,469 | 5,103,743 | 1,212,239 |
| General and administrative | 1,548,299 | 1,055,312 | 6,567,924 | 2,548,299 |
| Write-down of intellectual property rights | -- | -- | -- | -- |
| | <u>2,760,538</u> | <u>1,740,781</u> | <u>11,671,667</u> | <u>4,760,538</u> |
| Operating loss | (2,293,603) | (1,740,781) | (11,083,548) | (4,760,538) |
| Other income (expense): | | | | |
| Interest expense | (243,332) | -- | (1,010,648) | -- |
| Interest income | 48,922 | 2,555 | 60,638 | 48,922 |
| Other income | 113,312 | 33,534 | 225,541 | 113,312 |
| Other expense | -- | -- | -- | -- |
| | <u>(81,098)</u> | <u>36,089</u> | <u>(724,469)</u> | <u>--</u> |
| Loss from continuing operations | (2,374,701) | (1,704,692) | (11,808,017) | (3,704,692) |
| Loss from discontinued operations | -- | -- | -- | -- |
| Net loss | <u>\$ (2,374,701)</u> | <u>\$ (1,704,692)</u> | <u>\$ (11,808,017)</u> | <u>\$ (3,704,692)</u> |
| Loss per common share - basic and diluted | <u>\$ (0.03)</u> | <u>\$ (0.02)</u> | <u>\$ (0.16)</u> | <u>\$ (0.03)</u> |
| Weighted average shares outstanding | <u>76,760,163</u> | <u>70,029,872</u> | <u>75,430,870</u> | <u>68,760,163</u> |

See Notes to Condensed Consolidated Financial Statements.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

(Unaudited)

| | Nine Months Ended November 30, | |
|---|-----------------------------------|------------|
| | 2005 (Restated) | 2004 |
| | ----- | ----- |
| Cash flows used for operating activities: | | |
| Net loss | \$ (11,808,017) | \$ (3,958, |
| Adjustments to reconcile net loss to net cash used in operating activities: | | |
| Amortization of intangible assets | 40,929 | |
| Depreciation | 30,882 | 20, |
| Loss on disposal of equipment | 1,505 | |
| Realized and unrealized losses on marketable securities | -- | |
| Accrued interest on note converted to common stock | 19,506 | |
| Amortization of interest on convertible notes payable | -- | |
| Write-down of intellectual property rights | -- | |
| Amortization of discount on payable to related party | 958,160 | |
| Issuance of common stock for services | -- | |
| Issuance of common stock for interest | -- | |
| Grant of stock options for services | 4,644,202 | 110, |
| Expenses paid by stockholder | -- | |
| Minority interest | 26,523 | |
| Changes in operating assets and liabilities: | | |
| (Increase) decrease in due from related parties | 134,123 | (348, |
| (Increase) decrease in prepaid expenses | (84,345) | (36, |
| (Increase) decrease in other assets | (35,832) | |
| (Increase) decrease in security deposits | (867) | |
| Increase (decrease) in accounts payable and accrued expenses | 587,658 | 143, |
| Increase (decrease) in due to related parties | -- | |
| Increase (decrease) in deferred revenues | 275,000 | 225, |
| | ----- | ----- |
| Net cash used in operating activities | (5,210,573) | (3,843 |
| | ----- | ----- |
| Cash flows used for investing activities: | | |
| Purchases of property and equipment | (53,250) | (38, |
| Sales of marketable securities | -- | 1,150, |
| Purchase of investment | -- | (100, |
| Acquisition costs of intangible assets | (466,583) | |
| Cash paid for investment in Myotech, net of cash received of \$19,408 | (280,594) | |
| Cash paid for acquisition of Biophan Europe, net of cash received of \$107,956 | -- | |
| Purchases of marketable securities | -- | |
| | ----- | ----- |
| Net cash provided by (used in) investing activities | (800,427) | 1,011, |
| | ----- | ----- |

(CONTINUED ON FOLLOWING PAGE)

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

| | Nine Months Ended November 30, | |
|--|-----------------------------------|------------|
| | 2005 (Restated) | 2004 |
| | ----- | ----- |
| Cash flows provided by financing activities: | | |
| Proceeds of bridge loans | -- | -- |
| Loan from stockholder | -- | -- |
| Proceeds from line of credit borrowing - related party | 2,000,000 | -- |
| Line of credit payments - related party | (500,000) | -- |
| Repayment of note payable | (184,114) | -- |
| Proceeds from sales of capital stock | 6,050,000 | 1,655,000 |
| Exercise of options | 182,541 | 12,500 |
| Exercise of warrants | 20,707 | 811,300 |
| Swing profits | 295,362 | 306,720 |
| Deferred equity placement costs | -- | (22,100) |
| | ----- | ----- |
| Net cash provided by financing activities | 7,864,496 | 2,763,410 |
| | ----- | ----- |
| Net increase (decrease) in cash and cash equivalents | 1,853,496 | (68,510) |
| | ----- | ----- |
| Cash and cash equivalents, beginning | 753,288 | 823,900 |
| | ----- | ----- |
| Cash and cash equivalents, ending | \$ 2,606,784 | \$ 755,390 |
| | ===== | ===== |
| | ----- | ----- |
| Cash paid for interest | \$ 12,603 | \$ -- |
| | ===== | ===== |
| | ----- | ----- |
| Supplemental schedule of non-cash investing and financing activities: | | |
| Issuance of common stock for the acquisition of a 35% interest in Myotech, LLC | \$ 8,467,698 | \$ -- |
| | ===== | ===== |
| Allocation of proceeds from line of credit - related party to beneficial conversion feature and warrants | \$ 958,160 | \$ -- |
| | ===== | ===== |
| Issuance of common stock upon conversion of related party loans | \$ 1,000,000 | \$ -- |
| | ===== | ===== |
| Liabilities assumed in conjunction with acquisition of a 51% interest in Biophan Europe and certain intellectual property rights | \$ -- | \$ -- |
| | ===== | ===== |
| Intellectual property acquired through issuance of capital stock and assumption of related party payable | \$ -- | \$ -- |
| | ===== | ===== |
| Acquisition of intellectual property | \$ -- | \$ -- |
| | ===== | ===== |

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

| | | |
|--|-----------------|------------------|
| | ===== | ===== |
| Issuance of common stock upon conversion of bridge loans | \$ -- | \$ -- |
| | ===== | ===== |
| Common stock issued for subscription receivable | \$ -- | \$ 845,000 |
| | ===== | ===== |

See Notes to Condensed Consolidated Financial Statements.

5

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
November 30, 2005

INTERIM FINANCIAL STATEMENTS:

The condensed consolidated financial statements as of November 30, 2005 and for the three months and nine months ended November 30, 2005 and 2004 are unaudited. However, in the opinion of management of the Company, these financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary to present fairly the financial position and results of operations for such interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results to be obtained for a full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-KSB for the fiscal year ended February 28, 2005.

BASIS OF CONSOLIDATION:

The consolidated financial statements include the accounts of Biophan Technologies, Inc. ("Biophan"), its wholly owned subsidiaries, LTR Antisense Technology, Inc. ("Antisense") and Nanolution, LLC, formerly MRIC Drug Delivery Systems, LLC, ("Nanolution"), its majority owned subsidiaries Biophan Europe GmbH ("Biophan Europe"), formerly aMRIs GmbH, and TE Bio LLC ("TE Bio"), and Myotech, LLC ("Myotech"), a variable interest entity, collectively referred to as the "Company". All significant inter-company accounts and transactions have been eliminated in consolidation.

FASB Interpretation No. 46 (FIN-46R) (Revised December 2003), Consolidation of Variable Interest Entities, requires that if an enterprise is the primary beneficiary of a variable interest entity, the assets, liabilities and results of operations of the variable interest entity should be included in the consolidated financial statements of the enterprise.

COMPANY HISTORY:

The Company was incorporated under the laws of the State of Idaho on August 1, 1968 and on January 12, 2000, changed its domicile to Nevada by merging into a Nevada corporation, and on July 19, 2001, changed its name to Biophan Technologies, Inc. From the inception of the current line of business on December 1, 2000, the Company has not generated any material revenues. Therefore, the Company is in the development stage and will remain so until the realization of significant revenues. The Company's ability to continue in business is dependent upon obtaining sufficient financing or attaining future profitable operations.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

PRINCIPAL BUSINESS ACTIVITIES:

The primary mission is to develop and commercially exploit technologies for improving the performance, and as a result, the competitiveness of biomedical devices manufactured by third party companies. The Company possesses technologies for enabling biomedical devices, both implantable and those used in diagnostic and interventional procedures, to be safe (do not harm the patient or physician) and image compatible (allow effective imaging of the device and its surrounding tissue) with MRI (magnetic resonance imaging). The Company is also developing and marketing an image compatible ceramic motor; a system for generating power for implantable devices from body heat, and a series of implantable devices including MRI-visible vascular implants such as a vena cava filter, a heart valve and an occluder for the treatment of atrial septal defects, a hole in the wall separating the left and right chambers of the heart. The Company's first licensee for several of these technologies is Boston Scientific (NYSE: BSX). The Company is also an owner of a substantial minority interest, with rights to take a majority interest, in Myotech, (accounted for as a variable interest entity) developer of the MYO-VAD, a cardiac assist device that does not contact circulating blood and utilizes technology that has the potential to become a standard of care in the device market for treating multiple types of acute and chronic heart failure including congestive heart failure and sudden cardiac arrest.

ACCOUNTING FOR STOCK OPTIONS:

The Company has elected to apply Accounting Principles Board ("APB") Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations in accounting for its stock options issued to employees (intrinsic value) and has adopted the disclosure-only provisions of Statement of Financial Accounting Standards ("SFAS") No. 123, Accounting for Stock-Based Compensation. Had the Company elected to recognize compensation cost based on the fair value of the options granted at the grant date as prescribed by SFAS No. 123, the Company's net loss and loss per common share would have been as follows:

6

| | Three Months Ended November 30, 2005 | 2004 | Nine Months En 2005 |
|---|---|-------------------------|--------------------------|
| | ----- | ----- | ----- |
| Net loss - as reported | \$ (2,374,701) | \$ (1,704,692) | \$ (11,808,017) |
| Add: Stock-based employee compensation expense included in reported net loss, net of related tax effects | 29,500 | 40,000 | 4,355,030 |
| Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects | (220,466) | (74,000) | (6,279,291) |
| Net loss - pro forma | \$ (2,565,667) ===== | \$ (1,738,692) ===== | \$ (13,732,278) ===== |
| Basic and diluted loss per share - as reported | \$ (.03) ===== | \$ (.02) ===== | \$ (.16) ===== |
| Basic and diluted loss | | | |

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

| | | | | | | |
|-----------------------|-------|-------|-------|-------|-------|-------|
| per share - pro forma | \$ | (.03) | \$ | (.02) | \$ | (.18) |
| | ===== | | ===== | | ===== | |

In December 2004, the FASB issued SFAS No. 123 (revised 2004), "Share-Based Payment" ("SFAS No. 123R"), which replaces SFAS No. 123 and supersedes APB No. 25. SFAS No. 123R requires that the compensation cost relating to share-based payment transactions be recognized in financial statements based on alternative fair value models. The share-based compensation cost will be measured based on the fair value of the equity or liability instruments issued. Per APB No. 25, compensation expense was recognized only to the extent the fair value of common stock exceeded the stock option exercise price at the measurement date. In addition, the pro forma disclosures previously permitted under SFAS No. 123 no longer will be an alternative to financial statement recognition. SFAS No. 123R also requires the benefits of tax deductions in excess of recognized compensation cost to be reported as a financing cash flow rather than as an operating cash flow as required under current literature. Under the effective date provisions included in SFAS No. 123R, the Company would have been required to implement SFAS No. 123R as of the first interim or annual period that begins after June 15, 2005. On April 14, 2005, the SEC delayed the effective date which allows companies to implement SFAS No. 123R at the beginning of the first fiscal year after June 15, 2005, which would be March 1, 2006 for the Company. The Company is evaluating the requirements of SFAS No. 123R and expects that the adoption will have a material impact on the consolidated results of operations and earnings per share similar to the current pro-forma disclosures under SFAS No. 123, as per above.

For the nine months ended November 30, 2005, the non-cash charge to earnings for stock options granted was \$4,644,202 of which \$4,244,280 is related to the vesting, during the first and second quarters, of contingent options previously granted to executive officers and non-employee directors that vested on a contingent basis upon the achievement of specified performance-based milestones. These particular options, because they are not "fixed and determinable", do not qualify under the accounting rules for "disclosure only" treatment and accordingly, must be expensed for any intrinsic value at the time and to the extent that they vest. The calculated amounts resulted in a non-cash charge in the statement of operations and an offsetting credit to additional paid-in capital.

RECLASSIFICATION

For comparative purposes, certain amounts in the accompanying statement of operations for fiscal 2005 have been reclassified to conform to the presentation used for fiscal 2006. These reclassifications had no effect on previously reported results of operations or accumulated deficit.

REVENUE RECOGNITION:

The Company earns and recognizes revenue under development agreements when the phase of the agreement to which amounts relate is completed and the Company has no further performance obligation. Completion is determined by the attainment of specified milestones including a written progress report. Advance fees received on such agreements are deferred until recognized.

The Company recognizes initial license fees over the term of the related agreement. Revenue related to a performance milestone is recognized upon the achievement of the milestone, as defined in the respective agreements.

The Company recognizes revenues from testing services and consulting as services are performed.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

PREPAID EXPENSES:

Prepaid expenses comprise the following at November 30, 2005:

| | |
|--|-----------|
| Prepaid conference fees | \$ 50,300 |
| Prepaid insurance | 37,516 |
| Prepaid license fees to New Scale Technologies, Inc. - related company | 25,000 |
| Prepaid legal fees | 30,000 |
| Prepaid supplies | 18,125 |
| Prepaid royalties - related company | 15,000 |
| | ----- |
| | \$175,941 |
| | ===== |

INVESTMENT IN MYOTECH, LLC AND RESTATEMENT OF FINANCIAL STATEMENTS:

Effective November 30, 2005, we entered into a Securities Purchase Agreement for the acquisition of an initial 35% interest in Myotech, LLC ("Myotech"), a New York limited liability company, whereby we exchanged 4,923,080 shares of our common stock, par value \$.005, for 3,768,488 Class A (voting) units of Myotech. Under the Securities Purchase Agreement, we will also purchase for cash consideration of \$2.225 million an additional 811,037 Class A units of Myotech over a six-month period. We are obligated to issue the shares and fund the investment amount, subject to certain conditions. Further, at our discretion, we may purchase up to an additional 3,563,097 Class A units of Myotech for aggregate cash consideration of \$9.775 million upon achievement of certain milestones satisfactory to Biophan measured over a 24-month period. Upon the consummation of these additional elective milestone investments, we would hold a majority interest in Myotech.

This investment was previously accounted for using the equity method. However, the Company has re-evaluated its investment in Myotech and has determined that Myotech is a variable interest entity in accordance with FASB Interpretation No. 46 (FIN-46R) (Revised December 2003), Consolidation of Variable Interest Entities. The Company has further concluded that it is the primary beneficiary as defined by FIN-46R and, as a result, the Company is required to consolidate Myotech as of the date of acquisition of November 30, 2005. Therefore, the consolidated financial statements of the Company have been restated to include the accounts of Myotech, LLC. The principal impact of this consolidation is an increase in assets due to the recording of the value of intangible assets acquired of \$24,795,968, based on an independent appraisal, over the amount of the investment, and an increase in the amount of the minority interest representing outside interests in the equity of Myotech. Aggregate changes were as follows as of November 30, 2005:

| | As Previously Reported | Adjustments Increase (Decrease) | As Res |
|----------------------------|---------------------------|------------------------------------|--------|
| Intangible assets, net | \$ 956,809 | \$25,262,551 | \$ |
| Investment in Myotech, LLC | 11,105,053 | (11,105,053) | |
| Other assets | 3,125,504 | 906 | |

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

| | | | |
|--|-----------------|--------------|------|
| | \$ 15,187,366 | \$14,158,404 | \$ |
| | ===== | ===== | == |
| Liabilities | \$ 2,640,646 | \$ 303,451 | \$ |
| Minority interest | 26,523 | 15,725,725 | |
| Capital stock | 408,416 | -0- | |
| Additional paid-in capital | 41,405,072 | 6,596,926 | |
| Treasury stock | -0- | (8,467,698) | |
| Accumulated deficit | (29,293,291) | -0- | (|
| | \$ 15,187,366 | \$14,158,404 | \$ |
| | ===== | ===== | == |
| Operating loss-three months ended 11/30/05 | \$ (2,293,603) | -0- | \$ |
| | ===== | ===== | == |
| Net loss- three months ended 11/30/05 | \$ (2,374,701) | -0- | \$ |
| | ===== | ===== | == |
| Operating loss-nine months ended 11/30/05 | \$ (11,083,548) | -0- | \$ (|
| | ===== | ===== | == |
| Net loss- nine months ended 11/30/05 | \$ (11,808,017) | -0- | \$ (|
| | ===== | ===== | == |

The following is selected financial data for Myotech, LLC:

| | November 30, 2005 |
|----------------------|-------------------|
| Total current assets | \$ 26,908 |
| Intangible assets | 24,795,968 |
| Other assets | 33,298 |
| Total assets | \$ 24,856,174 |
| Current liabilities | \$ 662,751 |
| Equity | 24,193,423 |
| | \$ 24,856,174 |
| | ===== |

LINE OF CREDIT AGREEMENT:

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

On May 27, 2005, we entered into an unsecured loan agreement with Biomed Solutions LLC, a related company, whereby Biomed agreed to provide a line of credit facility of up to \$2 million. Borrowings under the line bear interest at 8% per annum, are payable on demand after August 31, 2006 and are convertible, at Biomed's election into the Company's common stock at 90% of the average closing price for the 20 trading days preceding the date of borrowings under the line. In June 2005, the Company borrowed the entire \$2 million under the line in two separate draws of \$1 million each and, in accordance with the agreement, Biomed received warrants to purchase 500,000 shares of the Company's common stock at an exercise price of 110% of the average closing price for the 20 trading days preceding the date of execution of the credit agreement. The Company recorded a discount on the borrowings of \$958,160 due to the beneficial conversion feature of the note as well as for the value of the warrants. The discount was amortized as additional interest expense over the term of the note and has been fully amortized as of November 30, 2005. On August 31, 2005, Biomed elected to convert \$1 million of the note plus accrued interest into 480,899 shares of common stock at which time, the remaining discount related to the \$1 million portion of the loan was fully expensed. On October 7, 2005, we repaid \$500,000 of principal and all accrued interest on the loan. During the quarter ended November 30, 2005 amortization of the discount on the note resulted in a non-cash interest expense of \$229,137. The balance of borrowings on the line was \$500,000 at November 30, 2005.

In addition, Biomed Solutions, LLC, has committed to provide us with a \$5 million credit facility at terms we believe to be competitive to comparable transactions in the event such credit is needed.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The discussion and analysis set forth below in this Item 2 have been amended to reflect the restatement of our consolidated financial statements for the period ended November 30, 2005, as described above in the Explanatory Note to this amended Quarterly on Form 10-Q and in the Note entitled "Investment in Myotech, LLC and Restatement of Financial Statements," to Condensed Consolidated Financial Statements included in Item 1 above. For this reason, the data set forth in this section may not be comparable to discussions and data in our previously filed Quarterly Reports.

All statements contained in this Item 2, unless they are specifically otherwise stated to be made as of a different date, are made as of January 17, 2006, the original filing date of our Quarterly Report on Form 10-Q for the period ended November 30, 2005, and do not reflect events occurring after the filing of our Quarterly Report on Form 10-Q filed on January 17, 2006 other than the restatement, and we undertake no obligation to update the forward-looking statements in this amended Quarterly Report on Form 10-Q.

General

Our primary mission is to develop and commercially exploit technologies for improving the performance, and the corresponding competitiveness, of biomedical devices manufactured by third party companies. We do not currently employ our own manufacturing or distribution channels but rather rely on relationships with sub-contractors and/or partner companies. We develop technology protected by strong intellectual property targeted at specific markets within the medical technology sector.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

Company Business

We are a technology development company with a strong focus on solving real-world technical challenges facing the medical device industry. When selecting a market opportunity to address, we generate a wide range of potential technical solutions. Each of the technical solutions that we pursue is strongly protected by intellectual property to ensure that we have the capability of effectively marketing our technologies. Whenever possible, we attempt to develop and patent multiple solutions for any given technology challenge. This is done both to strengthen our position against competitors, and to be in a position to offer multiple manufacturers alternative solutions, such as for MRI safety, or stent visibility, as we introduce our technologies to the market.

This approach has resulted in the development of a range of core technologies, and our presence in a number of different but related segments of the medical device market. We are aggressive in development and defense of our intellectual property assets and have an intellectual property portfolio several times the size of many comparable sized companies.

Over the past several quarters, we have been developing, or have acquired:

- o Technology to improve vascular stents so they can be imaged with MRI to detect the presence of restenosis (blockage) after implantation;
- o Technology to enable manufacture of an MR image compatible vena cava, which allows MR imaging of blood clots that may be present and therefore pose a risk to removal of the device;
- o Technology to enhance the MRI safety and MR image compatibility of pacemakers, cardio-defibrillators, neurostimulators, pain control devices, pumps, and virtually any implanted or interventional device which has elongated metal leads or metal components;
- o Technologies to enable improved MRI contrast agents;
- o Market opportunities for our MRI safe and image compatible ceramic motor, the Squiggle(TM) motor;
- o A system for generating power for implantable devices from body heat, in cooperation with NASA;
- o Technology to improve drug elution and drug delivery systems, including providing "active release" using non-invasive or minimally invasive activation; and
- o An improved ventricular assist device (VAD).

Licensing and Joint Venture Strategy

Boston Scientific License

On June 30, 2005, we entered into a licensing agreement with Boston Scientific Scimed, Inc. The agreement provides Boston Scientific with the right to use Biophan's MRI safety and image compatibility technology and other technologies in a broad range of exclusive and non-exclusive product areas at royalty rates of 3% to 5%. The exclusive product area includes vascular implants and the non-exclusive product area covers a broad array of medical devices. Boston Scientific has the right to sub-license the exclusive product areas to third parties, with Biophan and Boston Scientific to share all proceeds from these parties. The agreement also provides for milestone payments to Biophan for specific product areas which may be as high as several million dollars per product. In addition, the agreement required Boston Scientific to make an

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

initial upfront payment to Biophan of \$750,000 (which will not be an offset to future earned royalties); make annual minimum royalty and substantial annual earned royalty payments; and receive a right of first negotiation on new technologies acquired by Biophan in the fields of MRI safety and image compatibility. The initial \$750,000 payment was made on August 2, 2005 and will be recognized as revenue over the next twelve months. Accordingly, one-quarter of \$750,000, or \$187,500 was recorded as revenue in the current quarter ended November 30, 2005.

In December, 2005, we received \$250,000 for the first annual minimum payment under our license. The agreement calls for milestone payments upon achievement of significant project milestones, with some of these milestones in the multi-million dollar range, and requires payment of royalties for products sold incorporating our technologies. Boston Scientific has sublicensing rights to certain technologies, sharing revenue with Biophan, and other product lines will revert to Biophan in the event of non-performance. The agreement includes rights to our technology for making pacemakers, defibrillators and neurostimulators safe and image compatible for use with MRI. This agreement is available as an Exhibit to our 10-Q for the quarter ended August 31, 2005, as amended on January 9, 2005.

9

Acquisition of Intellectual Assets

We currently have an overall estate of 219 patents, including 163 U.S. patents, inclusive of those assigned and licensed, and including filed applications and allowed and issued patents. Of these, 48 U.S. patents have issued. Additionally, we have 56 international patents or applications in process.

We believe that a strong and broad intellectual property portfolio is vital to our ability to achieve and maintain royalties and product sales to major industrial partners across our product lines.

The technologies allowing visualization of implants have been developed at Biophan, and with technology partners under exclusive license, including aMRIs Patents GmbH in Germany (via an exclusive license); Aachen Resonance in Germany (via an exclusive license); and Nanoset, LLC in the U.S. (via an exclusive license). The patents include those licensed from Nanoset, LLC. Nanoset's technology can be used to reduce image artifacts caused by implantable and interventional medical devices.

The patents total also includes those licensed as part of the Biophan Europe acquisition whereby we obtained worldwide exclusive rights to a significant patent portfolio totaling fifteen issued and pending patents covering critical capabilities needed by the medical industry as the use of MRI interventional medicine and MRI diagnostics for examination of stents and other implants becomes standard medical procedure.

On an ongoing basis, we are aggressively pursuing internal research and development projects, as well as sourcing leading-edge providers of related technologies. We are currently reviewing several cardiovascular technologies which we feel have potential for exclusive licensing in, and subsequent product development and licensing out. Intellectual property, such as technology solutions and patents, may be developed internally, through joint ventures, licensed in, or purchased. To ensure the continuing value of our intellectual assets, we intend to aggressively defend our patents and licensed technology, both domestically and abroad.

Liquidity

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

On June 30, 2005, we executed a definitive equity investment agreement and a technology license with Boston Scientific Scimed. The equity transaction consists of the purchase of Biophan common stock totaling \$5 million, priced at \$3.02, which represents a 10% premium over the average of the closing price for the 30 calendar-day period prior to the closing. The technology license includes an upfront payment of \$750,000 and annual maintenance fees, in addition to royalties and milestone payments. Funding under both agreements occurred on August 2, 2005.

To ensure that we would have adequate cash on hand for pending activities, on May 27, 2005, Biomed Solutions LLC, an affiliate of Biophan, agreed to provide us with a line of credit facility of up to \$2 million. Borrowings under the line bear interest at 8% per annum and are convertible at 90% of the average closing price for the 20 trading days preceding the date of the borrowing. In June 2005, the full \$2 million was loaned and Biomed received warrant coverage of 500,000 shares priced at 110% of the average closing price for the 20 trading days preceding the date of execution of the credit agreement. The independent board members of Biophan negotiated and approved this credit facility. The terms of this credit facility are considered to be better than are available from commercial lending sources. On August 31, 2005, Biomed elected to convert \$1 million of the outstanding loan, plus accrued interest to date, into 480,899 shares of our common stock. On October 7, 2005, we repaid \$500,000 of principal plus all accrued interest on the outstanding loan. Biomed has extended the terms of our repayment of the remaining \$500,000.

On May 27, 2005, we cancelled a previous financing agreement and entered into a new agreement executed with SBI Brightline XI, LLC providing a \$30 million fixed price financing for 10,000,000 shares at an average price of \$3 per share, if we take the full facility, and with a range from \$2 a share to \$4 a share, which must be taken in sequential tranches of 1 million shares each. We amended this financial agreement on January 8, 2006 to clarify a minor ambiguity in the agreement related to the closing dates. There are no warrants or fees associated with this agreement. The financing requires the shares to be registered for resale.

Effective November 30, 2005, we entered into a Securities Purchase Agreement for the acquisition of an initial 35% interest in Myotech, LLC ("Myotech"), a New York limited liability company, whereby we exchanged 4,923,080 shares of our common stock, par value \$.005, for 3,768,488 Class A (voting) units of Myotech. Under the Securities Purchase Agreement, we will also purchase for cash consideration of \$2.225 million an additional 811,037 Class A units of Myotech over a six-month period. We are obligated to issue the shares and fund the investment amount, subject to certain conditions. Further, at our discretion, we may purchase up to an additional 3,563,097 Class A units of Myotech for aggregate cash consideration of \$9.775 million upon achievement of certain milestones satisfactory to Biophan measured over a 24-month period. Upon the consummation of these additional elective milestone investments, we would hold a majority interest in Myotech.

10

In addition, the independent committee received a fairness opinion from an NYSE-listed national investment banking firm stating that the transaction was fair to our stockholders from a financial point of view. This investment was previously accounted for using the equity method. However, the Company has re-evaluated its investment in Myotech and has determined that Myotech is a variable interest entity in accordance with FASB Interpretation No. 46 (FIN-46R) (Revised December 2003), Consolidation of Variable Interest Entities. The Company has further concluded that it is the primary beneficiary as defined by

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

FIN-46R and, as a result, the Company is required to consolidate Myotech as of the date of acquisition of November 30, 2005. Therefore, the consolidated financial statements of the Company have been restated to include the accounts of Myotech, LLC. The principal impact of this consolidation is an increase in assets due to the recording of the value of intangible assets acquired of \$24,795,968, based on an independent appraisal, over the amount of the investment, and an increase in the amount of the minority interest representing outside interests in the equity of Myotech.

Our affiliate Biomed Solutions, LLC, has committed to provide us with a \$5 million credit facility at terms we believe to be competitive to comparable transactions. Biomed Solutions is headed by Biophan CEO Michael Weiner, who is also a substantial beneficial owner of Biomed Solutions.

We believe that funding available under the SBI stock purchase agreement, the Biomed line of credit, and the Boston Scientific investment will provide the Company with adequate working capital resources for the upcoming 12 months of operations including the ability to fund, as needed, potential additional acquisitions and expansion of operations.

Our estimate of our cash requirements for the next twelve months is as follows:

| | (000's) |
|---|----------|
| | ----- |
| Research and product development expenses, including \$720,000 to fund Biophan Europe research and development | \$ 3,700 |
| Milestone investments in Myotech, LLC | 5,400 |
| General and administrative expenses, including administrative salaries and benefits, sales and marketing, program management, office expenses, rent expense, legal and accounting, publicity, and investor relations | 5,500 |
| | ----- |
| Total estimated cash requirements for next twelve months | \$14,600 |
| | ===== |

Results of Operations

The following comments discuss the significant factors affecting the consolidated operating results, financial condition and liquidity and cash flows of the Company for the three and nine-month periods ended November 30, 2005 as compared to the three and nine-month periods ended November 30, 2004. These comments should be read in conjunction with the Consolidated Financial Statements of the Company and Notes thereto included in the Company's Form 10-KSB for the fiscal year ended February 28, 2004.

Three Months Ended November 30, 2005 Compared to Three Months Ended November 30, 2004

Revenue. Revenues were \$0.467 million for the three months ended November 30, 2005 as compared to no revenues for the three months ended November 30, 2004. The increase is due to development contract payments and license fees from Boston Scientific Scimed, and operating revenues from our European subsidiary, which consisted primarily of MRI-related research and development consulting services to medical device manufacturers.

Research and Development. Research and development expenses increased by 77%, to approximately \$1.2 million for the 3 months ended November 30, 2005 from approximately \$0.685 million for the three months ended November 30, 2004 due primarily to expenses for Biophan Europe, patent attorney fees and accelerated

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

efforts in obtaining license rights.

General and Administrative. General and administrative expenses increased by 47% to approximately \$1.55 million for the 3 months ended November 30, 2005 from approximately \$1.06 million for the three months ended November 30, 2004 primarily due to increases in publicity, legal and consulting fees, and salaries.

Interest Expense. Interest expense of approximately \$0.24 million pertained to interest on borrowings under a line of credit extended from Biomed Solutions, LLC. The details of this agreement are described under the heading "Line of Credit Agreement."

11

Nine Months Ended November 30, 2005 Compared to Nine Months Ended November 30, 2004

Revenues.

Revenues were \$0.588 million for the nine months ended November 30, 2005 as compared to no revenues for the nine months ended November 30, 2004. The increase is due to development contract payments and license fees from Boston Scientific Scimed, and operating revenues from our European subsidiary, which consisted primarily of MRI-related research and development consulting services to medical device manufacturers.

Research and Development. Research and development expenses increased by 202% to approximately \$5.1 million for the 9 months ended November 30, 2005 from approximately \$1.7 million for the nine months ended November 30, 2004. due primarily to accelerated efforts in obtaining license rights, expenses for Biophan Europe, patent attorney fees, salaries, and additional compensation expense in the first and second quarters related to the vesting of contingent stock options.

General and Administrative. General and administrative expenses increased by 174% to \$6.57 million for the 9 months ended November 30, 2005 from approximately \$2.40 million for the nine months ended November 30, 2004. The increase in general and administrative expenses is primarily due to an increases publicity and investor relations, legal and consulting fees, salaries, and additional compensation expense in the first and second quarters related to the vesting of contingent stock options during the first nine months of 2005 as compared to last year.

Capital Resources

Our current strategic plan does not indicate a need for material capital expenditures in the conduct of research and development activities.

We currently employ twenty full-time individuals.

Forward Looking Statements

Forward looking statements in this Form 10-Q and in other documents incorporated herein, as well as in oral statements made by the Company, statements that are prefaced with the words "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "designed" and similar expressions, are intended to identify forward-looking statements regarding events, conditions, and financial trends that may affect the Company's future plans of operations, business strategy, results of operations and financial position. These statements are based on the Company's current expectations and estimates as to

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

prospective events and circumstances about which the Company can give no firm assurance. Further, any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement to reflect subsequent events or circumstances. Forward-looking statements should not be relied upon as a prediction of actual future financial condition or results. These forward-looking statements, like any forward-looking statements, involve risks and uncertainties that could cause actual results to differ materially from those projected or unanticipated.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Derivative Financial Instruments, Other Financial Instruments, and Derivative Commodity Instruments.

As of November 30, 2005, the Company did not participate in any derivative financial instruments, or other financial and commodity instruments for which fair value disclosure would be required under SFAS No. 107. Primary Market Risk Exposures

The Company's primary market risk exposures are in the areas of interest rate risk and foreign currency exchange rate risk. The Company's investment portfolio of cash equivalents is subject to interest rate fluctuations, but the Company believes this risk is immaterial due to the short-term nature of these investments. For the three months ended November 30, 2005, foreign currency translation gains were approximately \$1,600 as a result of consolidating the Company's foreign subsidiaries. During the period, the Company did not engage in any foreign currency hedging activities.

ITEM 4. CONTROLS AND PROCEDURES

(a) Restatement

FASB Interpretation No. 46 (FIN-46R) (Revised December 2003), Consolidation of Variable Interest Entities, requires that if an enterprise is the primary beneficiary of a variable interest entity, the assets, liabilities and results of operations of the variable interest entity should be included in the consolidated financial statements of the enterprise. The Company has invested in Myotech, LLC, (Myotech) a development stage business, and a developer of cardiac assist technologies. This investment was made on November 30, 2005 in the form of a Securities Purchase Agreement, whereby the Company received 3,768,488 Class A (voting) units for a 35% interest in Myotech, in exchange for 4,923,080 shares of our common stock valued at \$8,467,698. This investment was previously accounted for using the equity method.

The Company has re-evaluated its investment in Myotech and has determined that Myotech is a variable interest entity in accordance with FIN-46R. The Company has further concluded that it is the primary beneficiary as defined by FIN-46R and, as a result, the Company is required to consolidate Myotech as of the date of acquisition of November 30, 2005. Therefore, the consolidated financial statements of the Company included in this Report on Form 10-Q, have been restated to include the accounts of Myotech, LLC.

(b) Evaluation of Disclosure Controls and Procedures

In connection with the restatement, under the direction of our Chief Executive Officer and our Chief Financial Officer, we reevaluated our disclosure controls and procedures. We identified our failure to recognize and apply the correct criteria, as explained in FIN 46R, for the proper accounting for our investment in Myotech, LLC on November 30, 2005 as a material weakness in our internal control over financial reporting. Solely as a result of this material weakness, we concluded that our disclosure controls and procedures were not effective as of November 30, 2005, or for the quarterly periods ended February 28, 2006, May

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

31, 2006 and August 31, 2006.

(c) Remediation of Material Weakness in Internal Control

We are confident that, as of the date of this filing, we have fully remediated the material weaknesses in our internal control over financial reporting with respect to the item cited above. The remedial actions included:

- o Improving education and accounting reviews to ensure that personnel involved in entity investments and asset purchases understand and apply the pertinent accounting principles appropriate to the nature of the transaction.

In connection with this amended Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer have evaluated our disclosure controls and procedures as currently in effect and as a result of the remedial actions discussed above, have concluded that as of this date our disclosure controls and procedures are effective.

(d) Management's Report on Internal Control Over Financial Reporting (as restated)

The management of Biophan Technologies, Inc. is responsible for establishing and maintaining adequate internal control over financial reporting for the company. With the participation of the Chief Executive Officer and the Chief Financial Officer, our management conducted an evaluation of the effectiveness of our internal control over financial reporting as of November 30, 2005, February 28, 2006, May 31, 2006 and August 31, 2006, based on the framework and criteria established in Internal Control -- Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission.

In our Quarterly Report on Form 10-Q for the period ended November 30, 2005 (filed on January 17, 2006), in our Annual Report on Form 10-K for the year ended February 28, 2006 (originally filed on May 15, 2006 and amended on June 6, 2006) and in our Quarterly Reports on Form 10-Q for the periods ended May 31, 2006 (filed on July 10, 2006) and August 31, 2006 (filed on October 13, 2006) management concluded that our internal control over financial reporting was effective as of the end of the periods covered by such reports. Subsequently, management identified material weaknesses in internal control over financial reporting with respect to accounting for the investment in Myotech, LLC on November 30, 2005. Solely as a result of these material weaknesses, our management has revised its earlier assessment and has now concluded that our internal control over financial reporting was not effective as of November 30, 2005, or for the quarterly periods ended February 28, 2006, May 31, 2006 and August 31, 2006.

12

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We are not a party to any material legal proceedings and there are no material legal proceedings pending with respect to our property, except as noted below. We are not aware of any legal proceedings contemplated by any governmental authorities involving either us or our property. None of our directors, officers or affiliates is an adverse party in any legal proceedings involving us or our subsidiaries, or has an interest in any proceeding which is adverse to us or our subsidiaries.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

The Company is pursuing legal claims against one of its former law firms and certain of its attorneys. Review of the firm's work product and bills recently revealed questions about the firm's billing practices and other activities. The amount of potential damages has not yet been quantified. Also, the law firm has asserted claims seeking payment of additional legal fees, which claims the Company has denied. The litigation is in an early stage. While, as with any legal proceedings, no assurance can be given as to ultimate outcome, management believes that the outcome of the litigation will not have a material adverse effect upon the Company's financial condition.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On November 30, 2005, we entered into a Securities Purchase Agreement with Myotech, LLC, a New York limited liability corporation, whereby we issued to Myotech 4,923,080 previously authorized but unissued shares of our common stock, par value \$.005 per share, in exchange for 3,768,488 Class A units of Myotech. Our common stock was valued at \$1.72 per share, and the Myotech units were valued at \$2.7434 per unit. The shares were issued in a private placement exempt from the registration requirements of Section 5 of the Securities Act of 1933, as amended (the "Act"), pursuant to the exemption set forth in Section 4(2) of the Act. We did not receive any cash consideration for issuance of these shares of common stock. No underwriters were involved in the placement of the common stock. The shares are subject to the Rights Agreement entered into by and among us, the Myotech members and Myotech, dated as of November 30, 2005.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Submission of Matters to a Vote of Security Holders

Not applicable

Item 5. Other Information

Not applicable.

Item 6. Exhibits

13

| Exhibit No. | Exhibit Description | Location |
|-------------|---|------------------|
| 4.1 | Rights Agreement by and among Myotech, LLC the Members of Myotech, LLC, and Biophan Technologies, Inc. | Previously Filed |
| 4.2 | First Amendment to Line of Credit Agreement Between Biophan Technologies, Inc. and Biomed Solutions, LLC | Previously Filed |
| 4.3 | First Amendment to Convertible Promissory Note | Previously Filed |
| 10.1 | Securities Purchase Agreement between Biophan Technologies Inc. and Myotech, LLC., dated November 30, 2005 | Previously Filed |
| 10.2 | Letter Agreement, Amendment and Waiver of Certain Conditions to Closing, between Biophan Technologies and Myotech, LLC, dated December 21, 2005 | Previously Filed |
| 31.1 | Certification of C.E.O. pursuant to Rule 13a-14(a) | Filed herewith |
| 31.2 | Certification of C.F.O. pursuant to Rule 13a-14(a) | Filed herewith |

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 10-Q/A

- 32.1 Certification of C.E.O. pursuant to Rule 13a-14(b) and 18 U.S.C. Section 1350 Filed herewith
- 32.2 Certification of C.F.O. pursuant to Rule 13a-14(b) and 18 U.S.C. Section 1350 Filed herewith

14

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BIOPHAN TECHNOLOGIES, INC.

(Registrant)

By: /s/ Michael L. Weiner

Name: Michael L. Weiner,
Title: Chief Executive Officer

By: /s/ Darryl L. Canfield

Name: Darryl L. Canfield
Title: Chief Financial Officer, Treasurer and Secretary
(Principal Financial Officer and Principal Accounting Officer)

Date: January 24, 2007

15